Atlas Trials

Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma

Clinical trial NCT01093222 · COMPLETED

Trial details

NCT number
NCT01093222
Sponsor
National Cancer Institute (NCI)
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Extrahepatic Bile Duct AdenocarcinomaGallbladder AdenocarcinomaGallbladder Adenocarcinoma With Squamous MetaplasiaHilar CholangiocarcinomaRecurrent Extrahepatic Bile Duct CarcinomaRecurrent Gallbladder CarcinomaUndifferentiated Gallbladder CarcinomaUnresectable Extrahepatic Bile Duct CarcinomaUnresectable Gallbladder Carcinoma
Start date
2010-04-01
Primary completion
2012-09-01
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.